

***APOE*ε4 carriership associates with microglial activation independently of Aβ plaques and tau tangles**

João Pedro Ferrari-Souza^{1,2†}, Firoza Z. Lussier^{1,3†}, Douglas T. Leffa^{1,4}, Joseph Therriault³, Cécile Tissot^{1,3}, Bruna Bellaver^{1,2}, Pâmela C. Lukasewicz Ferreira¹, Maura Malpetti⁵, Yi-Ting Wang³, Guilherme Povala², Andréa L. Benedet^{3,6}, Nicholas J. Ashton^{6,7,8}, Mira Chamoun³, Stijn Servaes³, Gleb Bezgin³, Min Su Kang³, Jenna Stevenson³, Nesrine Rahmouni³, Vanessa Pallen³, Nina Margherita Poltronetti³, John T. O'Brien^{5,9}, James B. Rowe^{5,10}, Ann D. Cohen¹, Oscar L. Lopez¹¹, Dana L. Tudorascu¹, Thomas K. Karikari^{1,6,12}, William E. Klunk¹, Victor L. Villemagne¹, Jean-Paul Soucy¹³, Serge Gauthier³, Diogo O. Souza², Henrik Zetterberg^{6,12,14,15,16}, Kaj Blennow^{6,12}, Eduardo R. Zimmer^{2,17,18}, Pedro Rosa-Neto³, and Tharick A. Pascoal^{1*}

¹Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA. ²Graduate Program in Biological Sciences: Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. ³Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, Alzheimer's Disease Research Unit, Douglas Research Institute, Le Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal; Department of Neurology and Neurosurgery, Psychiatry and Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada. ⁴ADHD Outpatient Program & Development Psychiatry Program, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. ⁵Department of Clinical Neurosciences, Cambridge

University Hospitals NHS Trust, University of Cambridge, Cambridge, UK. ⁶Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. ⁷Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway. ⁸Department of Old Age Psychiatry, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. ⁹Department of Psychiatry, University of Cambridge, Cambridge, UK. ¹⁰MRC Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK. ¹¹Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA. ¹²Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden. ¹³Montreal Neurological Institute, McGill University, Montreal, QC, Canada. ¹⁴Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK. ¹⁵UK Dementia Research Institute at UCL, London, UK. ¹⁶Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China. ¹⁷Department of Pharmacology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. ¹⁸Graduate Program in Biological Sciences: Pharmacology and Therapeutics, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil

*Corresponding author. Email: pascoalt@upmc.edu.

†First authors contributed equally to this work.

Abstract

Microglial activation is an early phenomenon in Alzheimer's disease (AD) that may occur prior to and independently of amyloid- β (A β) aggregation. Recent studies in transgenic animal models suggest that the apolipoprotein E ϵ 4 (*APOE ϵ 4*) allele may be a culprit of early microglial activation in AD. However, it is unclear whether the *APOE ϵ 4* genotype is associated with microglial reactivity in the living human brain. Here, we tested whether *APOE ϵ 4* carriership is associated with microglial activation in individuals across the aging and AD spectrum. We studied 118 individuals who had positron emission tomography (PET) for A β ($[^{18}\text{F}]$ AZD4694), tau ($[^{18}\text{F}]$ MK6240), and microglial activation ($[^{11}\text{C}]$ PBR28), as well as clinical, genetic, and magnetic resonance imaging data. We found that *APOE ϵ 4* carriership was associated with increased microglial activation mainly in early Braak-staging regions within the medial temporal cortex, and this effect of *APOE ϵ 4* was independent of A β and tau deposition. Furthermore, microglial activation mediated the A β -independent effects of *APOE ϵ 4* on downstream tau accumulation, neurodegeneration, and clinical impairment. Interestingly, the physiological distribution of *APOE* mRNA expression, obtained from the Allen Human Atlas, predicted the patterns of *APOE ϵ 4*-related microglial activation in our population, suggesting that the deleterious effects of *APOE ϵ 4* occur at the level of gene expression. These results support a model in which the *APOE ϵ 4* has A β -independent effects on AD pathogenesis by activating microglia in brain regions associated with early tau deposition. Our findings provide a rationale for the development of novel AD therapies targeting the interplay between ApoE and neuroinflammation.

Introduction

Alzheimer's disease (AD) is a multifactorial disorder neuropathologically characterized by amyloid- β (A β) plaques and tau neurofibrillary tangles (1, 2). Among the multiple pathogenic processes involved in AD etiology, neuroinflammation - commonly associated with microglial reactivity - has been increasingly recognized (3, 4). Microglial activation plays a key role in the accumulation of AD hallmark proteinopathies, rather than being merely an epiphenomenon of their deposition (3, 4). Specifically, recent observations from animal and human studies suggest that microglial activation precedes and may drive tau spread over the neocortex following a Braak stage-like pattern (5-7), from the medial temporal to association and primary sensory structures (8-11). Such microglial activation is synaptotoxic, affects brain connectivity, and predicts clinical decline (12, 13). A β pathology can trigger microglial activation in AD (14-16), but A β plaques and activated microglia only partially overlap topographically in the human brain (17-19), and microglial activation may occur prior to demonstrable A β deposition (3).

The apolipoprotein E ϵ 4 (*APOE ϵ 4*) allele is a major genetic risk factor for sporadic AD (20-23). The link between *APOE ϵ 4* and A β deposition is an important factor leading to AD progression (24). However, recent animal studies suggest that the *APOE ϵ 4* genotype may also contribute to AD pathogenesis through A β -independent pathways by potentiating brain inflammation, tau accumulation, and neurodegeneration (25, 26). Although robust experimental evidence indicates that the *APOE* genotype modulates microglial response in AD (25, 27-30), it remains to be elucidated whether *APOE ϵ 4* carriership is associated with microglial activation in the AD human brain. The characterization of this association in living

individuals is critical to confirm the A β -independent detrimental effects of *APOE* ϵ 4 on microglia homeostasis and to support the development of novel therapeutic strategies.

Using complementary positron emission tomography (PET) radiotracers for the topographical quantification of microglial activation, A β , and tau accumulation across the brain, we investigated the association of *APOE* ϵ 4 carriership, microglial activation, A β , and tau in a cohort of individuals across the aging and AD continuum. We hypothesized that *APOE* ϵ 4 is associated with microglial activation independently of AD hallmark proteinopathies. We then tested whether microglial activation mediates the effects of *APOE* ϵ 4 on tau accumulation, neurodegeneration, and clinical impairment. *Postmortem* data from the Allen Human Brain Atlas was used to test the link between regional levels of brain *APOE* gene expression and the distribution of microglial activation as a function of *APOE* ϵ 4 carriership.

Results

Participants

We screened 606 people for the rs6971 polymorphism in the translocator protein (*TSPO*) gene. Out of the 314 high-affinity binders, we studied 118 individuals that were across the aging and AD spectrum (79 cognitively unimpaired [CU], 23 with mild cognitive impairment [MCI], and 16 with AD dementia) with [18 F]AZD4694 A β PET, [18 F]MK6240 tau PET, [11 C]PBR28 microglial activation PET, and magnetic resonance imaging (MRI), as well as *APOE* genotyping (**Fig. S1**). Demographic characteristics of the population are reported in

Table 1. Information regarding the prevalence of *APOE* genotypes in our sample is described in **Table S1**.

***APOE*ε4 associates with microglial activation in the medial temporal cortex**

To test the association between *APOE*ε4 status and [¹¹C]PBR28 microglial activation PET, we conducted linear regression analyses adjusting for age, sex, and clinical diagnosis. Voxel-wise regression analysis showed that *APOE*ε4 carriership was associated with higher [¹¹C]PBR28 uptake mainly in medial temporal structures (transentorhinal, entorhinal, and hippocampal cortices), which are regions corresponding to early Braak stages (**Fig. 1A, B**). Regarding the spatial extent of the voxel-wise results, the association between *APOE*ε4 carriership and [¹¹C]PBR28 (SUVR) was predominantly observed in areas corresponding to Braak I (affecting 94.8% of this region), followed by Braak II (47.6%), Braak III (16.7%), Braak IV (13.1%), Braak V (2.5%), and Braak VI regions (1.0%; **Fig. 1C**). Similarly, in terms of the magnitude of the associations (β estimate), the relationship between *APOE*ε4 and [¹¹C]PBR28 uptake was progressively weaker from Braak I to VI, surviving Bonferroni correction for multiple comparisons only in Braak I and II regions (Braak I: $\beta = 0.088$, 95% confidence interval [CI] 0.044 to 0.133, $P < 0.001$; Braak II: $\beta = 0.066$, 95% CI 0.020 to 0.111, $P = 0.005$; **Fig. 1D**). Sensitivity analysis excluding individuals bearing the ε2 allele of the *APOE* gene showed similar findings (**Fig. S2**).

***APOE* ϵ 4 associates with microglial activation independently of A β and tau biomarkers**

We investigated whether the association between *APOE* ϵ 4 carriership and [¹¹C]PBR28 uptake was independent of AD hallmark proteinopathies by correcting the regression models for global [¹⁸F]AZD4694 A β PET and local [¹⁸F]MK6240 tau PET, as well as age, sex, and clinical diagnosis. *APOE* ϵ 4 carriership was associated with higher [¹¹C]PBR28 uptake in Braak I-II regions independently of global A β and local tau PET ($\beta = 0.055$, 95% CI 0.010 to 0.100, $P = 0.018$; **Table 2**). In a subgroup of 51 participants (31 CU, 12 with MCI, and 8 with AD dementia), we conducted sensitivity analyses adjusting for cerebrospinal fluid (CSF) A β ₁₋₄₂ and p-tau₁₈₁ instead of [¹⁸F]AZD4694 A β PET and [¹⁸F]MK6240 tau PET, respectively. Demographics for the subgroup of participants are presented in **Table S2**. Similarly, we found that *APOE* ϵ 4 carriership was significantly associated with higher [¹¹C]PBR28 SUVR in Braak I-II regions independently of CSF A β ₁₋₄₂ and p-tau₁₈₁ ($\beta = 0.073$, 95% CI 0.005 to 0.140, $P = 0.035$; **Table S3**), which reinforces the cross-modality imaging results. Exploratory analyses conducted across the six Braak regions supported that the A β - and tau-independent association of *APOE* ϵ 4 carriership with [¹¹C]PBR28 uptake was mainly confined to early Braak regions, either assessing AD hallmark proteins with imaging ([¹⁸F]AZD4694 A β PET and [¹⁸F]MK6240 tau PET; **Table S4**) or fluid biomarkers (CSF A β ₁₋₄₂ and p-tau₁₈₁; **Table S5**).

***APOE* gene expression resembles *APOE* ϵ 4-related microglial activation patterns**

We studied the topographical distribution of *APOE* messenger RNA (mRNA) in the *postmortem* brain of six CU individuals from the Allen Human Brain Atlas. We observed different *APOE* gene expression levels across Braak regions, which were progressively lower

from Braak I to VI (**Fig. 2A**), suggesting that the cerebral levels of *APOE* gene expression partially follow Braak-like stages. Additionally, linear regressions demonstrated that the regional patterns of Allen *APOE* mRNA expression across Braak regions predicted the topography and magnitude of *APOE* ϵ 4 effects on [¹¹C]PBR28 uptake observed in our population (**Fig. 2B, C**).

Microglial activation mediates the A β -independent effects of *APOE* ϵ 4 on downstream AD markers

We next used structural equation modeling to investigate the associations between *APOE* ϵ 4, microglial activation, A β , tau, hippocampal volume, and clinical function (as measured with the clinical dementia rating scale sum of boxes [CDR-SB] score). We found that an increase in [¹¹C]PBR28 microglial activation uptake partially mediated the effects of *APOE* ϵ 4 carriership on higher tau PET uptake in Braak I-II regions independently of A β PET burden. The model also showed the well-reported effects of *APOE* ϵ 4 on higher tau PET uptake through higher A β PET load, which were independent of microglial activation. Notably, both A β -independent and -dependent pathways leading to medial temporal tau pathology were further associated with lower hippocampal volume and, ultimately, higher severity of clinical impairment (**Fig. 3**). This model fit the data well ($n = 118$, $\chi^2 = 7.141$, degrees of freedom = 5, $P = 0.210$, root mean squared error of approximation [RMSEA] = 0.060, standardized root mean square residual [SRMR] = 0.023, comparative fit index [CFI] = 0.991). Complete model coefficients and associated statistics are described in **Table S6**.

Discussion

In the present study, we observed that *APOE* ϵ 4 carriership was associated with microglial activation in early Braak-stage regions independently of AD hallmark proteinopathies. We also found that the brain distribution of *APOE* gene expression predicted the pattern of *APOE* ϵ 4-related microglial activation observed in our study population. Lastly, we demonstrated that microglial activation partially mediated the *APOE* ϵ 4 effects on regional tau accumulation through an A β -independent pathway, which was further associated with neurodegeneration and clinical impairment. Taken together, our findings support the hypothesis that *APOE* ϵ 4 contributes to the early progression of AD via increased neuroinflammation.

APOE ϵ 4 carriership was associated with higher levels of microglial activation in living humans across the aging and AD continuum. Several recent investigations in animal models of AD support our findings. For example, the *APOE* genotype modulates microglial response in AD, with *APOE* ϵ 4 being associated with multiple microglial-related detrimental downstream effects (*e.g.*, protein aggregation, neurodegeneration, and dysfunctional immunometabolic response) (25, 27-30). Further experiments showed that the *APOE* ϵ 4 genotype associates with changes in the transcriptional profile of microglia from a homeostatic state to a disease-associated state across AD progression (31, 32) and that the activation of microglial-related proteins (*e.g.*, triggering receptor expressed on myeloid cells 2 (TREM2) (33-36)) is directly associated with ApoE signaling (37). This evidence raises the possibility that the mechanisms explaining the link between ApoE and microglial activation occur at the transcriptional level by the expression of microglia-specific genes such as *TREM2*. Altogether, the aforementioned findings suggest that the *APOE* ϵ 4 genotype is

associated with a disruption in microglia homeostasis in AD, promoting disease-associated microglia that plays a role in the development of the disease.

Our results showed an effect of *APOE* ϵ 4 on medial temporal microglial activation leading to AD progression that is partially independent of A β and tau. Previous observations indicate that microglial activation may precede and drive tau propagation (5-7, 38). Moreover, an investigation using the [¹¹C]PK11195 PET tracer found that microglial activation in the temporal lobe is associated with longitudinal cognitive decline more strongly than the [¹⁸F]AV1451 tau PET tracer binding in patients presenting AD pathophysiology (12). We complemented these reports by demonstrating an A β -independent effect of *APOE* ϵ 4 on early microglial activation in medial temporal structures, which in turn mediate tau accumulation and AD progression. These results resonate with recent CSF biomarker evidence of neuroinflammation in adult *APOE* ϵ 4 carriers who have not developed A β pathology yet (39). Our findings are also in line with animal model studies showing that the *APOE* genotype affects tau pathology as well as tau-mediated neurodegeneration independently of A β , with the *APOE* ϵ 4 isoform having detrimental effects on both outcomes (25, 38, 40-42). In humans, *APOE* ϵ 4 carriership has been associated with medial temporal atrophy (43-46). Additionally, a recent study revealed that *APOE* ϵ 4 carriership is associated with tau PET uptake in the medial temporal lobe independently of A β , raising discussions about the importance of elucidating the biological underpinnings of this association (47). We built on these previous investigations suggesting that microglial activation is the mediator of the A β -independent effects of *APOE* ϵ 4 on medial temporal tau deposition and brain atrophy, leading to dementia. Together, these results suggest that disease-modifying therapies targeting the interplay

between ApoE and microglial activation have the potential to slow downstream AD progression.

Interestingly, we observed that cerebral *APOE* mRNA expression was more prominent in medial temporal structures and its levels hierarchically followed the Braak staging scheme. Even though the Allen Human Brain Atlas is derived from younger adults without dementia, the *APOE* gene expression pattern was able to predict the topography and magnitude of the *APOE* ϵ 4-related [¹¹C]PBR28 uptake increase in our cohort. It is well-established that tau neurofibrillary tangles follow a stereotypical pattern of progression known as Braak stages, with tau tangles deposition starting in the medial temporal cortex (8-11). Microglial activation precedes and drives tau spread from the medial temporal lobe to the neocortex in a Braak-like pattern in AD models (5-7), although the mechanism associated with triggering microglial activation in medial temporal structures was not fully understood. Here, we first showed that *APOE* ϵ 4 plays a role in triggering microglia activation in early Braak regions, and second that a Braak-like pattern of *APOE* gene expression could shed light on the entire hierarchical progression of tau across these stages. These results indicate that microglia-mediated tau propagation in AD might be explained at least partially by the cerebral expression levels of ApoE4.

Methodological strengths of the present work include the assessment of a well-characterized cohort with multiple PET radiotracers acquired on the same scanner, which allows high-quality topographical characterization of microglial activation, A β deposition, and tau accumulation using the best currently available technologies. Moreover, we screened a large sample of 606 individuals for the rs6971 polymorphism in the *TSPO* gene, and, consequently, we were able to include only high-affinity binders for the [¹¹C]PBR28 radiotracer, which

increases the signal-to-noise ratio of the tracer and the reliability of our results. Methodological limitations need to be acknowledged and considered to interpret our results. The [^{11}C]PBR28 radiotracer binds to the TSPO, which is a protein mainly expressed in the mitochondrial outer membrane of activated microglia (3). Thus, [^{11}C]PBR28 PET is considered an imaging biomarker of a general cerebral microglial activation state (7, 48, 49). However, it is recognized that microglia may acquire diverse phenotypes across disease progression (3), and this heterogeneity cannot be captured using the available human brain imaging technologies. Furthermore, it is possible that other cell types (*e.g.*, astrocytes) also play a minor role in the TSPO PET signal (3, 50-53). Because CSF measures have been suggested to detect A β and tau accumulation earlier than PET (48, 54, 55), the fact we observed similar results using imaging ([^{18}F]AZD4694 and [^{18}F]MK6240) and fluid (CSF A β_{1-42} and p-tau $_{181}$) biomarkers support the robustness of our findings. However, we cannot exclude a possible contribution of pre-fibrillary A β and tau aggregates to our results. Future studies using multiple longitudinal measures are needed to better evaluate the sequential relationship between neuroimaging biomarkers. Lastly, individuals included in our investigation were volunteers motivated to participate in a study about AD, which can be a source of self-selection bias.

In conclusion, our results support the existence of an A β -independent effect of *APOE* ϵ 4 on AD progression through microglial activation, leading to tau accumulation, neurodegeneration, and eventually clinical impairment.

Materials and methods

Experimental design

The main objective of the present study was to test the association between *APOE*ε4 carriership and brain levels of microglial activation. We hypothesized that *APOE*ε4 is associated with microglial activation in early Braak regions independently of Aβ and tau pathologies. Furthermore, we aimed to assess whether microglial activation mediates the effects of *APOE*ε4 on downstream AD progression. Participants from the community or outpatients at the McGill University Research Centre for Studies in Aging were enrolled in the Translational Biomarkers in Aging and Dementia (TRIAD) study (<https://triad.tnl-mcgill.com>). Participants were required to have adequate visual and auditory capacities for neuropsychological assessment, as well as the ability to speak English or French. Additionally, individuals were not enrolled if they had active substance abuse, major surgery, recent head trauma, neuroimaging contraindication, simultaneously being enrolled in other studies, and untreated neurological, psychiatric, or systemic conditions. This study was approved by the Douglas Mental Health University Institute Research Ethics Board and the Montreal Neurological Institute PET working committee, and all participants provided written informed consent.

Participants

Out of the 606 individuals screened for the rs6971 polymorphism in the *TSPO* gene, we studied 118 individuals with high-affinity binding aged 52 to 87 years (79 CU, 23 with MCI, and 16 with AD dementia). At the same time point, all participants had PET for Aβ

($[^{18}\text{F}]$ AZD4694), tau tangles ($[^{18}\text{F}]$ MK6240), and microglial activation ($[^{11}\text{C}]$ PBR28), as well as MRI and *APOE* genotyping. Two individuals that had $[^{11}\text{C}]$ PBR28 or $[^{18}\text{F}]$ MK6240 SUVR values three standard deviations (SD) above the mean of the population were considered outliers as defined *a priori* and excluded from the analyses. A flowchart describing the selection of study participants is reported in **Fig. S1**. Participants underwent detailed neuropsychological assessments, including Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR). CU subjects had no objective cognitive impairment and a global CDR score of 0. MCI patients had subjective and objective cognitive impairment, preserved activities of daily living, and a global CDR score of 0.5 (56). Mild-to-moderate AD dementia patients had a global CDR score between 0.5 and 2 and met the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable AD (57). We analyzed all the individuals with complete data, and no power analysis was performed before the study. It is worth noting that the sample size of the present work is similar to the largest previous TSPO PET studies across the AD spectrum (7, 58-60).

Genetic data

$[^{11}\text{C}]$ PBR28 binding affinity is influenced by a common polymorphism (rs6971) in the *TSPO* gene (<https://www.ncbi.nlm.nih.gov/snp/rs6971>). In order to increase the reliability of our results, we genotyped 606 participants for the rs6971 polymorphism before imaging, and we only included high-affinity binders (7). Noteworthy, this polymorphism is a methodological caveat and does not affect TSPO levels, glial activity, or AD pathological changes (53). Moreover, subjects were genotyped for the *APOE* gene using the polymerase chain reaction

amplification technique, followed by restriction enzyme digestion, standard gel resolution, and visualization processes (61).

Brain imaging

T₁-weighted MRIs were acquired at the Montreal Neurological Institute (MNI) using a 3T Siemens Magnetom. We used the magnetization prepared rapid acquisition gradient echo (MPRAGE) MRI (TR: 2300 ms, TE: 2.96ms) sequence to obtain high-resolution structural images of the whole brain (9° flip angle, coronal orientation perpendicular to the double spin echo sequence, 1x1 mm² in-plane resolution of 1 mm slab thickness) (62). Aβ PET with [¹⁸F]AZD4694 (40–70 min post-injection), tau PET with [¹⁸F]MK-6240 (90–110 min post-injection), and microglial activation TSPO PET with [¹¹C]PBR28 (60–90 min post-injection) were acquired at the MNI using a Siemens High Resolution Research Tomograph. PET scans were reconstructed using the ordered subset expectation maximization (OSEM) algorithm on a four-dimensional (4D) volume with three frames (3 x 600 seconds) for [¹⁸F]AZD4694 PET (63), four frames (4 x 300 seconds) for [¹⁸F]MK-6240 PET (63), and six frames (6 × 300 s) for [¹¹C]PBR28 PET (7). Then, attenuation correction was performed using a 6-minute transmission scan with a rotating ¹³⁷Cs point source. Furthermore, PET images were corrected for motion, dead time, decay, and scattered and random coincidences. Following an in-house pipeline, T₁-weighted MRIs were corrected for non-uniformity and field distortion. Subsequently, linear co-registration and non-linear spatial normalization for the ADNI template were performed through linear and non-linear transformation in two main steps: (i) PET registration to the correspondent T₁-weighted MRI and (ii) T₁-weighted MRI registration to the ADNI reference space. PET images were spatially smoothed to achieve a

final resolution of 8 mm full width at half-maximum. SUVRs were calculated using the whole cerebellum gray matter for [¹⁸F]AZD4694 A β PET (64) and [¹¹C]PBR28 microglial activation PET (7), and the inferior cerebellum gray matter for [¹⁸F]MK-6240 tau PET (65). The Desikan-Killiany-Tourville atlas was used to determine the regions of interest (ROIs) (66). A global A β PET SUVR was estimated from the precuneus, prefrontal, orbitofrontal, parietal, temporal, and cingulate cortices (67). Based on *postmortem* observations (8, 9) and PET studies (65, 68), PET Braak-like stages were calculated from brain regions corresponding to the Braak stages of tau neurofibrillary tangle accumulation: Braak I (transentorhinal), Braak II (entorhinal and hippocampus), Braak III (amygdala, parahippocampal gyrus, fusiform gyrus, lingual gyrus), Braak IV (insula, inferior temporal, lateral temporal, posterior cingulate, and inferior parietal), Braak V (orbitofrontal, superior temporal, inferior frontal, cuneus, anterior cingulate, supramarginal gyrus, lateral occipital, precuneus, superior parietal, superior frontal, rostro medial frontal), and Braak VI (paracentral, postcentral, precentral, and pericalcarine) (65, 69). A representation of the Braak-like regions used in our analysis is shown in **Fig. S3**. Hippocampal volume was adjusted for total intracranial volume using MRI data from CU subjects (70).

The Allen Human Brain Atlas (<http://www.brain-map.org>) (71) was used to obtain information regarding *APOE* gene expression in the brain. In brief, microarray was used to calculate mRNA expression intensity values on 3702 samples from 6 healthy human *postmortem* brains (4 males, mean age = 42.5 (13.4) years, *postmortem* delay = 20.6 (7) hours). The *APOE* mRNA brain expression maps were derived from a Gaussian process (72) and downloaded from www.meduniwien.ac.at/neuroimaging/mRNA.html.

CSF measurements

A subgroup of 51 individuals had CSF A β ₁₋₄₂ and p-tau₁₈₁ quantified using the LUMIPULSE G1200 instrument (Fujirebio) at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden (73).

Statistical analysis

Analyses were performed in the R software (version 4.0.2, <http://www.r-project.org/>). Neuroimaging analyses were conducted using RMINC (74), an imaging package that allows the integration of voxel-based statistics into the R statistical environment. Voxel-wise and ROI-based linear regressions tested the association between *APOE* ϵ 4 status (noncarrier or carrier) and microglial activation indexed by the [¹¹C]PBR28 SUVR adjusting for age, sex, and clinical diagnosis (CU, MCI, or AD). To further investigate whether this association was independent of AD hallmark proteins, ROI-based models were also adjusted for A β ([¹⁸F]AZD4694 PET or CSF A β ₁₋₄₂) and tau ([¹⁸F]MK-6240 PET or CSF p-tau₁₈₁) biomarkers. Multiple comparison correction at $P < 0.05$ was performed using random field theory for voxel-wise analysis and Bonferroni method for ROI-based analysis when appropriate. We calculated the percentage of voxels in each Braak region showing an association (T -value > 2) between *APOE* ϵ 4 carriership and [¹¹C]PBR28 SUVR in the aforementioned voxel-wise analysis. Regression analysis tested whether the *APOE* mRNA expression intensity predicted the topography and magnitude of *APOE* ϵ 4-related [¹¹C]PBR28 SUVR increase across Braak regions. Structural equation modeling, R package “lavaan” (75), was used to test the associations between *APOE* ϵ 4 status, microglial activation, A β , tau, hippocampal volume, and clinical function (as measured with the CDR-SB score). All the

associations in the model were adjusted for age and sex; associations involving hippocampal volume and clinical deterioration were further adjusted for years of education. Structural equation model was judged as having a good fit as follows: CFI > 0.97 (acceptable: 0.95 - 0.97); RMSEA < 0.05 (acceptable 0.05 - 0.08); SRMR < 0.05 (acceptable: 0.05 - 0.10) (76, 77). Statistical significance of parameters estimates from the structural equation model was tested using bootstrapping with 1000 permutations. For all analyses, two-tailed *P*-values < 0.05 were considered statistically significant.

List of Supplementary Materials

Fig. S1. Flowchart of included participants.

Fig. S2. Sensitivity analysis excluding *APOE*ε2 carriers.

Fig. S3. Braak regions mask used in the analyses.

Table S1. Prevalence of *APOE* genotypes.

Table S2. Demographics of the subsample with available CSF biomarkers.

Table S3. Sensitivity analysis testing the association of *APOE*ε4 carriership with microglial activation adjusting for CSF Aβ₁₋₄₂ and p-tau₁₈₁.

Table S4. Associations between microglial activation and *APOE*ε4 carriership across all Braak regions adjusting for global [¹⁸F]AZD4694 Aβ PET and local [¹⁸F]MK6240 tau PET.

Table S5. Associations between microglial activation and *APOE*ε4 carriership across all Braak regions adjusting for CSF Aβ₁₋₄₂ and p-tau₁₈₁.

Table S6. Structural equation model coefficients and associated statistics for Fig. 3.

References and Notes

1. J. C. Polanco, C. Li, L. G. Bodea, R. Martinez-Marmol, F. A. Meunier, J. Gotz, Amyloid-beta and tau complexity - towards improved biomarkers and targeted therapies. *Nat Rev Neurol* **14**, 22-39 (2018).
2. D. S. Knopman, H. Amieva, R. C. Petersen, G. Chetelat, D. M. Holtzman, B. T. Hyman, R. A. Nixon, D. T. Jones, Alzheimer disease. *Nat Rev Dis Primers* **7**, 33 (2021).
3. F. Leng, P. Edison, Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here? *Nat Rev Neurol* **17**, 157-172 (2021).
4. M. T. Heneka, M. J. Carson, J. El Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, K. Herrup, S. A. Frautschy, B. Finsen, G. C. Brown, A. Verkhratsky, K. Yamanaka, J. Koistinaho, E. Latz, A. Halle, G. C. Petzold, T. Town, D. Morgan, M. L. Shinohara, V. H. Perry, C. Holmes, N. G. Bazan, D. J. Brooks, S. Hunot, B. Joseph, N. Deigendesch, O. Garaschuk, E. Boddeke, C. A. Dinarello, J. C. Breitner, G. M. Cole, D. T. Golenbock, M. P. Kummer, Neuroinflammation in Alzheimer's disease. *Lancet Neurol* **14**, 388-405 (2015).
5. C. Ising, C. Venegas, S. Zhang, H. Scheiblich, S. V. Schmidt, A. Vieira-Saecker, S. Schwartz, S. Albasset, R. M. McManus, D. Tejera, A. Griep, F. Santarelli, F. Brosseron, S. Opitz, J. Stunden, M. Merten, R. Kaye, D. T. Golenbock, D. Blum, E. Latz, L. Buee, M. T. Heneka, NLRP3 inflammasome activation drives tau pathology. *Nature* **575**, 669-673 (2019).

6. S. C. Hopp, Y. Lin, D. Oakley, A. D. Roe, S. L. DeVos, D. Hanlon, B. T. Hyman, The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. *J Neuroinflammation* **15**, 269 (2018).
7. T. A. Pascoal, A. L. Benedet, N. J. Ashton, M. S. Kang, J. Therriault, M. Chamoun, M. Savard, F. Z. Lussier, C. Tissot, T. K. Karikari, J. Ottoy, S. Mathotaarachchi, J. Stevenson, G. Massarweh, M. Scholl, M. J. de Leon, J. P. Soucy, P. Edison, K. Blennow, H. Zetterberg, S. Gauthier, P. Rosa-Neto, Microglial activation and tau propagate jointly across Braak stages. *Nat Med* **27**, 1592-1599 (2021).
8. H. Braak, E. Braak, Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* **82**, 239-259 (1991).
9. H. Braak, E. Braak, Frequency of stages of Alzheimer-related lesions in different age categories. *Neurobiol Aging* **18**, 351-357 (1997).
10. H. Braak, I. Alafuzoff, T. Arzberger, H. Kretschmar, K. Del Tredici, Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. *Acta Neuropathol* **112**, 389-404 (2006).
11. H. Braak, D. R. Thal, E. Ghebremedhin, K. Del Tredici, Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. *J Neuropathol Exp Neurol* **70**, 960-969 (2011).
12. M. Malpetti, R. A. Kievit, L. Passamonti, P. S. Jones, K. A. Tsvetanov, T. Rittman, E. Mak, N. Nicastro, W. R. Bevan-Jones, L. Su, Y. T. Hong, T. D. Fryer, F. I. Aigbirhio, J. T. O'Brien, J. B. Rowe, Microglial activation and tau burden predict cognitive decline in Alzheimer's disease. *Brain* **143**, 1588-1602 (2020).
13. L. Passamonti, K. A. Tsvetanov, P. S. Jones, W. R. Bevan-Jones, R. Arnold, R. J. Borchert, E. Mak, L. Su, J. T. O'Brien, J. B. Rowe, Neuroinflammation and

- Functional Connectivity in Alzheimer's Disease: Interactive Influences on Cognitive Performance. *J Neurosci* **39**, 7218-7226 (2019).
14. A. Hayes, U. Thaker, T. Iwatsubo, S. M. Pickering-Brown, D. M. Mann, Pathological relationships between microglial cell activity and tau and amyloid beta protein in patients with Alzheimer's disease. *Neurosci Lett* **331**, 171-174 (2002).
 15. M. Kitazawa, T. R. Yamasaki, F. M. LaFerla, Microglia as a potential bridge between the amyloid beta-peptide and tau. *Ann N Y Acad Sci* **1035**, 85-103 (2004).
 16. P. L. McGeer, E. G. McGeer, The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. *Acta Neuropathol* **126**, 479-497 (2013).
 17. A. Serrano-Pozo, M. L. Mielke, T. Gomez-Isla, R. A. Betensky, J. H. Growdon, M. P. Frosch, B. T. Hyman, Reactive glia not only associates with plaques but also parallels tangles in Alzheimer's disease. *Am J Pathol* **179**, 1373-1384 (2011).
 18. P. Parbo, R. Ismail, K. V. Hansen, A. Amidi, F. H. Marup, H. Gottrup, H. Braendgaard, B. O. Eriksson, S. F. Eskildsen, T. E. Lund, A. Tietze, P. Edison, N. Pavese, M. G. Stokholm, P. Borghammer, R. Hinz, J. Aanerud, D. J. Brooks, Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimer's disease. *Brain* **140**, 2002-2011 (2017).
 19. M. Dani, M. Wood, R. Mizoguchi, Z. Fan, Z. Walker, R. Morgan, R. Hinz, M. Biju, T. Kuruvilla, D. J. Brooks, P. Edison, Microglial activation correlates in vivo with both tau and amyloid in Alzheimer's disease. *Brain* **141**, 2740-2754 (2018).
 20. L. A. Farrer, L. A. Cupples, J. L. Haines, B. Hyman, W. A. Kukull, R. Mayeux, R. H. Myers, M. A. Pericak-Vance, N. Risch, C. M. van Duijn, Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer

- disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. *JAMA* **278**, 1349-1356 (1997).
21. E. Genin, D. Hannequin, D. Wallon, K. Sleegers, M. Hiltunen, O. Combarros, M. J. Bullido, S. Engelborghs, P. De Deyn, C. Berr, F. Pasquier, B. Dubois, G. Tognoni, N. Fievet, N. Brouwers, K. Bettens, B. Arosio, E. Coto, M. Del Zompo, I. Mateo, J. Epelbaum, A. Frank-Garcia, S. Helisalmi, E. Porcellini, A. Pilotto, P. Forti, R. Ferri, E. Scarpini, G. Siciliano, V. Solfrizzi, S. Sorbi, G. Spalletta, F. Valdivieso, S. Vepsalainen, V. Alvarez, P. Bosco, M. Mancuso, F. Panza, B. Nacmias, P. Bossu, O. Hanon, P. Piccardi, G. Annoni, D. Seripa, D. Galimberti, F. Licastro, H. Soininen, J. F. Dartigues, M. I. Kamboh, C. Van Broeckhoven, J. C. Lambert, P. Amouyel, D. Campion, APOE and Alzheimer disease: a major gene with semi-dominant inheritance. *Mol Psychiatry* **16**, 903-907 (2011).
 22. J. C. Lambert, C. A. Ibrahim-Verbaas, D. Harold, A. C. Naj, R. Sims, C. Bellenguez, A. L. DeStafano, J. C. Bis, G. W. Beecham, B. Grenier-Boley, G. Russo, T. A. Thorton-Wells, N. Jones, A. V. Smith, V. Chouraki, C. Thomas, M. A. Ikram, D. Zelenika, B. N. Vardarajan, Y. Kamatani, C. F. Lin, A. Gerrish, H. Schmidt, B. Kunkle, M. L. Dunstan, A. Ruiz, M. T. Bihoreau, S. H. Choi, C. Reitz, F. Pasquier, C. Cruchaga, D. Craig, N. Amin, C. Berr, O. L. Lopez, P. L. De Jager, V. Deramecourt, J. A. Johnston, D. Evans, S. Lovestone, L. Letenneur, F. J. Moron, D. C. Rubinsztein, G. Eiriksdottir, K. Sleegers, A. M. Goate, N. Fievet, M. W. Huentelman, M. Gill, K. Brown, M. I. Kamboh, L. Keller, P. Barberger-Gateau, B. McGuinness, E. B. Larson, R. Green, A. J. Myers, C. Dufouil, S. Todd, D. Wallon, S. Love, E. Rogaeva, J. Gallacher, P. St George-Hyslop, J. Clarimon, A. Lleó, A. Bayer, D. W. Tsuang, L. Yu, M. Tsolaki, P. Bossu, G. Spalletta, P. Proitsi, J. Collinge, S.

- Sorbi, F. Sanchez-Garcia, N. C. Fox, J. Hardy, M. C. Deniz Naranjo, P. Bosco, R. Clarke, C. Brayne, D. Galimberti, M. Mancuso, F. Matthews, I. European Alzheimer's Disease, Genetic, D. Environmental Risk in Alzheimer's, C. Alzheimer's Disease Genetic, H. Cohorts for, E. Aging Research in Genomic, S. Moebus, P. Mecocci, M. Del Zompo, W. Maier, H. Hampel, A. Pilotto, M. Bullido, F. Panza, P. Caffarra, B. Nacmias, J. R. Gilbert, M. Mayhaus, L. Lannefelt, H. Hakonarson, S. Pichler, M. M. Carrasquillo, M. Ingelsson, D. Beekly, V. Alvarez, F. Zou, O. Valladares, S. G. Younkin, E. Coto, K. L. Hamilton-Nelson, W. Gu, C. Razquin, P. Pastor, I. Mateo, M. J. Owen, K. M. Faber, P. V. Jonsson, O. Combarros, M. C. O'Donovan, L. B. Cantwell, H. Soininen, D. Blacker, S. Mead, T. H. Mosley, Jr., D. A. Bennett, T. B. Harris, L. Fratiglioni, C. Holmes, R. F. de Bruijn, P. Passmore, T. J. Montine, K. Bettens, J. I. Rotter, A. Brice, K. Morgan, T. M. Foroud, W. A. Kukull, D. Hannequin, J. F. Powell, M. A. Nalls, K. Ritchie, K. L. Lunetta, J. S. Kauwe, E. Boerwinkle, M. Riemenschneider, M. Boada, M. Hiltunen, E. R. Martin, R. Schmidt, D. Rujescu, L. S. Wang, J. F. Dartigues, R. Mayeux, C. Tzourio, A. Hofman, M. M. Nothen, C. Graff, B. M. Psaty, L. Jones, J. L. Haines, P. A. Holmans, M. Lathrop, M. A. Pericak-Vance, L. J. Launer, L. A. Farrer, C. M. van Duijn, C. Van Broeckhoven, V. Moskvina, S. Seshadri, J. Williams, G. D. Schellenberg, P. Amouyel, Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* **45**, 1452-1458 (2013).
23. E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. *Science* **261**, 921-923 (1993).

24. D. M. Holtzman, J. Herz, G. Bu, Apolipoprotein E and apolipoprotein E receptors: normal biology and roles in Alzheimer disease. *Cold Spring Harb Perspect Med* **2**, a006312 (2012).
25. Y. Shi, K. Yamada, S. A. Liddelow, S. T. Smith, L. Zhao, W. Luo, R. M. Tsai, S. Spina, L. T. Grinberg, J. C. Rojas, G. Gallardo, K. Wang, J. Roh, G. Robinson, M. B. Finn, H. Jiang, P. M. Sullivan, C. Baufeld, M. W. Wood, C. Sutphen, L. McCue, C. Xiong, J. L. Del-Aguila, J. C. Morris, C. Cruchaga, I. Alzheimer's Disease Neuroimaging, A. M. Fagan, B. L. Miller, A. L. Boxer, W. W. Seeley, O. Butovsky, B. A. Barres, S. M. Paul, D. M. Holtzman, ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. *Nature* **549**, 523-527 (2017).
26. Y. Yamazaki, N. Zhao, T. R. Caulfield, C. C. Liu, G. Bu, Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol* **15**, 501-518 (2019).
27. C. D. Keene, E. Cudaback, X. Li, K. S. Montine, T. J. Montine, Apolipoprotein E isoforms and regulation of the innate immune response in brain of patients with Alzheimer's disease. *Curr Opin Neurobiol* **21**, 920-928 (2011).
28. Y. T. Lin, J. Seo, F. Gao, H. M. Feldman, H. L. Wen, J. Penney, H. P. Cam, E. Gjoneska, W. K. Raja, J. Cheng, R. Rueda, O. Kritskiy, F. Abdurrob, Z. Peng, B. Milo, C. J. Yu, S. Elmsaouri, D. Dey, T. Ko, B. A. Yankner, L. H. Tsai, APOE4 Causes Widespread Molecular and Cellular Alterations Associated with Alzheimer's Disease Phenotypes in Human iPSC-Derived Brain Cell Types. *Neuron* **98**, 1141-1154 e1147 (2018).

29. G. A. Rodriguez, L. M. Tai, M. J. LaDu, G. W. Rebeck, Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. *J Neuroinflammation* **11**, 111 (2014).
30. S. Lee, N. A. Devanney, L. R. Golden, C. T. Smith, J. L. Schwarz, A. E. Walsh, H. A. Clarke, D. S. Goulding, E. J. Allenger, G. Morillo-Segovia, C. M. Friday, A. A. Gorman, T. R. Hawkinson, S. M. MacLean, H. C. Williams, R. C. Sun, J. M. Morganti, L. A. Johnson, *APOE* modulates microglial immunometabolism in response to age, amyloid pathology, and inflammatory challenge. *bioRxiv*, 2022.2005.2017.492361 (2022).
31. H. Keren-Shaul, A. Spinrad, A. Weiner, O. Matcovitch-Natan, R. Dvir-Szternfeld, T. K. Ulland, E. David, K. Baruch, D. Lara-Astaiso, B. Toth, S. Itzkovitz, M. Colonna, M. Schwartz, I. Amit, A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. *Cell* **169**, 1276-1290 e1217 (2017).
32. S. Parhizkar, D. M. Holtzman, APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. *Semin Immunol*, 101594 (2022).
33. T. Jonsson, H. Stefansson, S. Steinberg, I. Jonsdottir, P. V. Jonsson, J. Snaedal, S. Bjornsson, J. Huttenlocher, A. I. Levey, J. J. Lah, D. Rujescu, H. Hampel, I. Giegling, O. A. Andreassen, K. Engedal, I. Ulstein, S. Djurovic, C. Ibrahim-Verbaas, A. Hofman, M. A. Ikram, C. M. van Duijn, U. Thorsteinsdottir, A. Kong, K. Stefansson, Variant of TREM2 associated with the risk of Alzheimer's disease. *N Engl J Med* **368**, 107-116 (2013).
34. R. Guerreiro, A. Wojtas, J. Bras, M. Carrasquillo, E. Rogaevea, E. Majounie, C. Cruchaga, C. Sassi, J. S. Kauwe, S. Younkin, L. Hazrati, J. Collinge, J. Pocock, T. Lashley, J. Williams, J. C. Lambert, P. Amouyel, A. Goate, R. Rademakers, K.

- Morgan, J. Powell, P. St George-Hyslop, A. Singleton, J. Hardy, G. Alzheimer Genetic Analysis, TREM2 variants in Alzheimer's disease. *N Engl J Med* **368**, 117-127 (2013).
35. Y. Shi, D. M. Holtzman, Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. *Nat Rev Immunol* **18**, 759-772 (2018).
36. T. R. Jay, V. E. von Saucken, G. E. Landreth, TREM2 in Neurodegenerative Diseases. *Mol Neurodegener* **12**, 56 (2017).
37. S. Krasemann, C. Madore, R. Cialic, C. Baufeld, N. Calcagno, R. El Fatimy, L. Beckers, E. O'Loughlin, Y. Xu, Z. Fanek, D. J. Greco, S. T. Smith, G. Tweet, Z. Humulock, T. Zrzavy, P. Conde-Sanroman, M. Gacias, Z. Weng, H. Chen, E. Tjon, F. Mazaheri, K. Hartmann, A. Madi, J. D. Ulrich, M. Glatzel, A. Worthmann, J. Heeren, B. Budnik, C. Lemere, T. Ikezu, F. L. Heppner, V. Litvak, D. M. Holtzman, H. Lassmann, H. L. Weiner, J. Ochando, C. Haass, O. Butovsky, The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases. *Immunity* **47**, 566-581 e569 (2017).
38. Y. Shi, M. Manis, J. Long, K. Wang, P. M. Sullivan, J. Remolina Serrano, R. Hoyle, D. M. Holtzman, Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model. *J Exp Med* **216**, 2546-2561 (2019).
39. E. Konijnenberg, B. M. Tijms, J. Gobom, V. Dobricic, I. Bos, S. Vos, M. Tsolaki, F. Verhey, J. Popp, P. Martinez-Lage, R. Vandenberghe, A. Lleo, L. Frolich, S. Lovestone, J. Streffer, L. Bertram, K. Blennow, C. E. Teunissen, R. Veerhuis, A. B. Smit, P. Scheltens, H. Zetterberg, P. J. Visser, APOE epsilon4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. *Alzheimers Res Ther* **12**, 65 (2020).

40. A. Litvinchuk, T. V. Huynh, Y. Shi, R. J. Jackson, M. B. Finn, M. Manis, C. M. Francis, A. C. Tran, P. M. Sullivan, J. D. Ulrich, B. T. Hyman, T. Cole, D. M. Holtzman, Apolipoprotein E4 Reduction with Antisense Oligonucleotides Decreases Neurodegeneration in a Tauopathy Model. *Ann Neurol* **89**, 952-966 (2021).
41. C. Wang, M. Xiong, M. Gratuze, X. Bao, Y. Shi, P. S. Andhey, M. Manis, C. Schroeder, Z. Yin, C. Madore, O. Butovsky, M. Artyomov, J. D. Ulrich, D. M. Holtzman, Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia. *Neuron* **109**, 1657-1674 e1657 (2021).
42. R. Mancuso, G. Fryatt, M. Cleal, J. Obst, E. Papi, J. Monzon-Sandoval, E. Ribe, L. Winchester, C. Webber, A. Nevado, T. Jacobs, N. Austin, C. Theunis, K. Grauwen, E. Daniela Ruiz, A. Mudher, M. Vicente-Rodriguez, C. A. Parker, C. Simmons, D. Cash, J. Richardson, N. Consortium, D. N. C. Jones, S. Lovestone, D. Gomez-Nicola, V. H. Perry, CSF1R inhibitor JNJ-40346527 attenuates microglial proliferation and neurodegeneration in P301S mice. *Brain* **142**, 3243-3264 (2019).
43. C. Geroldi, M. Pihlajamaki, M. P. Laakso, C. DeCarli, A. Beltramello, A. Bianchetti, H. Soininen, M. Trabucchi, G. B. Frisoni, APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. *Neurology* **53**, 1825-1832 (1999).
44. L. O'Dwyer, F. Lamberton, S. Matura, C. Tanner, M. Scheibe, J. Miller, D. Rujescu, D. Prvulovic, H. Hampel, Reduced hippocampal volume in healthy young ApoE4 carriers: an MRI study. *PLoS One* **7**, e48895 (2012).
45. R. de Flores, S. Demeilliez-Servouin, E. Kuhn, L. Chauveau, B. Landeau, N. Delcroix, J. Gonneaud, G. Chételat, Effects of amyloid and *APOE4* on

- medial temporal lobe subregions in cognitively unimpaired elderly. *medRxiv*, 2022.2001.2020.22269607 (2022).
46. M. Donix, A. C. Burggren, N. A. Suthana, P. Siddarth, A. D. Ekstrom, A. K. Krupa, M. Jones, A. Rao, L. Martin-Harris, L. M. Ercoli, K. J. Miller, G. W. Small, S. Y. Bookheimer, Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. *Neuroimage* **53**, 37-43 (2010).
 47. J. Therriault, A. L. Benedet, T. A. Pascoal, S. Mathotaarachchi, M. Chamoun, M. Savard, E. Thomas, M. S. Kang, F. Lussier, C. Tissot, M. Parsons, M. N. I. Qureshi, P. Vitali, G. Massarweh, J. P. Soucy, S. Rej, P. Saha-Chaudhuri, S. Gauthier, P. Rosa-Neto, Association of Apolipoprotein E epsilon4 With Medial Temporal Tau Independent of Amyloid-beta. *JAMA Neurol* **77**, 470-479 (2020).
 48. H. Zetterberg, B. B. Bendlin, Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies. *Mol Psychiatry* **26**, 296-308 (2021).
 49. K. E. Hopperton, D. Mohammad, M. O. Trepanier, V. Giuliano, R. P. Bazinet, Markers of microglia in post-mortem brain samples from patients with Alzheimer's disease: a systematic review. *Mol Psychiatry* **23**, 177-198 (2018).
 50. S. Venneti, G. Wang, J. Nguyen, C. A. Wiley, The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. *J Neuropathol Exp Neurol* **67**, 1001-1010 (2008).
 51. S. Lavis, M. Guillermier, A. S. Herard, F. Petit, M. Delahaye, N. Van Camp, L. Ben Haim, V. Lebon, P. Remy, F. Dolle, T. Delzescaux, G. Bonvento, P. Hantraye, C. Escartin, Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. *J Neurosci* **32**, 10809-10818 (2012).

52. M. Pannell, V. Economopoulos, T. C. Wilson, V. Kersemans, P. G. Isenegger, J. R. Larkin, S. Smart, S. Gilchrist, V. Gouverneur, N. R. Sibson, Imaging of translocator protein upregulation is selective for pro-inflammatory polarized astrocytes and microglia. *Glia* **68**, 280-297 (2020).
53. Y. Gui, J. D. Marks, S. Das, B. T. Hyman, A. Serrano-Pozo, Characterization of the 18 kDa translocator protein (TSPO) expression in post-mortem normal and Alzheimer's disease brains. *Brain Pathol* **30**, 151-164 (2020).
54. S. Palmqvist, N. Mattsson, O. Hansson, I. Alzheimer's Disease Neuroimaging, Cerebrospinal fluid analysis detects cerebral amyloid-beta accumulation earlier than positron emission tomography. *Brain* **139**, 1226-1236 (2016).
55. M. Bucci, K. Chiotis, A. Nordberg, I. Alzheimer's Disease Neuroimaging, Alzheimer's disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline. *Mol Psychiatry* **26**, 5888-5898 (2021).
56. R. C. Petersen, Mild cognitive impairment as a diagnostic entity. *J Intern Med* **256**, 183-194 (2004).
57. G. M. McKhann, D. S. Knopman, H. Chertkow, B. T. Hyman, C. R. Jack, Jr., C. H. Kawas, W. E. Klunk, W. J. Koroshetz, J. J. Manly, R. Mayeux, R. C. Mohs, J. C. Morris, M. N. Rossor, P. Scheltens, M. C. Carrillo, B. Thies, S. Weintraub, C. H. Phelps, The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement* **7**, 263-269 (2011).
58. J. Zou, S. Tao, A. Johnson, Z. Tomljanovic, K. Polly, J. Klein, Q. R. Razlighi, A. M. Brickman, S. Lee, Y. Stern, W. C. Kreisl, Microglial activation, but not tau pathology,

- is independently associated with amyloid positivity and memory impairment. *Neurobiol Aging* **85**, 11-21 (2020).
59. T. Terada, M. Yokokura, T. Obi, T. Bunai, E. Yoshikawa, I. Ando, H. Shimada, T. Sahara, M. Higuchi, Y. Ouchi, In vivo direct relation of tau pathology with neuroinflammation in early Alzheimer's disease. *J Neurol* **266**, 2186-2196 (2019).
 60. S. Bradburn, C. Murgatroyd, N. Ray, Neuroinflammation in mild cognitive impairment and Alzheimer's disease: A meta-analysis. *Ageing Res Rev* **50**, 1-8 (2019).
 61. A. J. Saykin, L. Shen, X. Yao, S. Kim, K. Nho, S. L. Risacher, V. K. Ramanan, T. M. Foroud, K. M. Faber, N. Sarwar, L. M. Munsie, X. Hu, H. D. Soares, S. G. Potkin, P. M. Thompson, J. S. Kauwe, R. Kaddurah-Daouk, R. C. Green, A. W. Toga, M. W. Weiner, I. Alzheimer's Disease Neuroimaging, Genetic studies of quantitative MCI and AD phenotypes in ADNI: Progress, opportunities, and plans. *Alzheimers Dement* **11**, 792-814 (2015).
 62. J. P. Ferrari-Souza, P. C. Lukasewicz Ferreira, B. Bellaver, C. Tissot, Y.-T. Wang, D. T. Leffa, W. S. Brum, A. L. Benedet, N. J. Ashton, M. A. De Bastiani, A. Rocha, J. Therriault, F. Z. Lussier, M. Chamoun, S. Servaes, G. Bezgin, M. S. Kang, J. Stevenson, N. Rahmouni, V. Pallen, N. M. Poltronetti, W. E. Klunk, D. L. Tudorascu, A. Cohen, V. L. Villemagne, S. Gauthier, K. Blennow, H. Zetterberg, D. O. Souza, T. K. Karikari, E. R. Zimmer, P. Rosa-Neto, T. A. Pascoal, Astrocyte biomarker signatures of amyloid- β and tau pathologies in Alzheimer's disease. *medRxiv*, 2022.2001.2025.22269841 (2022).
 63. T. A. Pascoal, M. Shin, M. S. Kang, M. Chamoun, D. Chartrand, S. Mathotaarachchi, I. Bennacef, J. Therriault, K. P. Ng, R. Hopewell, R. Bouhachi, H. H. Hsiao, A. L.

- Benedet, J. P. Soucy, G. Massarweh, S. Gauthier, P. Rosa-Neto, In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240. *Alzheimers Res Ther* **10**, 74 (2018).
64. Z. Cselenyi, M. E. Jonhagen, A. Forsberg, C. Halldin, P. Julin, M. Schou, P. Johnstrom, K. Varnas, S. Svensson, L. Farde, Clinical validation of 18F-AZD4694, an amyloid-beta-specific PET radioligand. *J Nucl Med* **53**, 415-424 (2012).
65. T. A. Pascoal, J. Therriault, A. L. Benedet, M. Savard, F. Z. Lussier, M. Chamoun, C. Tissot, M. N. I. Qureshi, M. S. Kang, S. Mathotaarachchi, J. Stevenson, R. Hopewell, G. Massarweh, J. P. Soucy, S. Gauthier, P. Rosa-Neto, 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. *Brain* **143**, 2818-2830 (2020).
66. A. Klein, J. Tourville, 101 labeled brain images and a consistent human cortical labeling protocol. *Front Neurosci* **6**, 171 (2012).
67. C. R. Jack, Jr., H. J. Wiste, S. D. Weigand, T. M. Therneau, V. J. Lowe, D. S. Knopman, J. L. Gunter, M. L. Senjem, D. T. Jones, K. Kantarci, M. M. Machulda, M. M. Mielke, R. O. Roberts, P. Vemuri, D. A. Reyes, R. C. Petersen, Defining imaging biomarker cut points for brain aging and Alzheimer's disease. *Alzheimers Dement* **13**, 205-216 (2017).
68. M. Scholl, S. N. Lockhart, D. R. Schonhaut, J. P. O'Neil, M. Janabi, R. Ossenkoppele, S. L. Baker, J. W. Vogel, J. Faria, H. D. Schwimmer, G. D. Rabinovici, W. J. Jagust, PET Imaging of Tau Deposition in the Aging Human Brain. *Neuron* **89**, 971-982 (2016).
69. T. A. Pascoal, A. L. Benedet, D. L. Tudorascu, J. Therriault, S. Mathotaarachchi, M. Savard, F. Z. Lussier, C. Tissot, M. Chamoun, M. S. Kang, J. Stevenson, G. Massarweh, M. C. Guiot, J. P. Soucy, S. Gauthier, P. Rosa-Neto, Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. *Brain*, (2021).

70. T. I. Hansen, V. Brezova, L. Eikenes, A. Haberg, T. R. Vangberg, How Does the Accuracy of Intracranial Volume Measurements Affect Normalized Brain Volumes? Sample Size Estimates Based on 966 Subjects from the HUNT MRI Cohort. *AJNR Am J Neuroradiol* **36**, 1450-1456 (2015).
71. M. J. Hawrylycz, E. S. Lein, A. L. Guillozet-Bongaarts, E. H. Shen, L. Ng, J. A. Miller, L. N. van de Lagemaat, K. A. Smith, A. Ebbert, Z. L. Riley, C. Abajian, C. F. Beckmann, A. Bernard, D. Bertagnolli, A. F. Boe, P. M. Cartagena, M. M. Chakravarty, M. Chapin, J. Chong, R. A. Dalley, B. David Daly, C. Dang, S. Datta, N. Dee, T. A. Dolbeare, V. Faber, D. Feng, D. R. Fowler, J. Goldy, B. W. Gregor, Z. Haradon, D. R. Haynor, J. G. Hohmann, S. Horvath, R. E. Howard, A. Jeromin, J. M. Jochim, M. Kinnunen, C. Lau, E. T. Lazarz, C. Lee, T. A. Lemon, L. Li, Y. Li, J. A. Morris, C. C. Overly, P. D. Parker, S. E. Parry, M. Reding, J. J. Royall, J. Schulkin, P. A. Sequeira, C. R. Slaughterbeck, S. C. Smith, A. J. Sodt, S. M. Sunkin, B. E. Swanson, M. P. Vawter, D. Williams, P. Wohnoutka, H. R. Zielke, D. H. Geschwind, P. R. Hof, S. M. Smith, C. Koch, S. G. N. Grant, A. R. Jones, An anatomically comprehensive atlas of the adult human brain transcriptome. *Nature* **489**, 391-399 (2012).
72. G. Gryglewski, R. Seiger, G. M. James, G. M. Godbersen, A. Komorowski, J. Unterholzner, P. Michenthaler, A. Hahn, W. Wadsak, M. Mitterhauser, S. Kasper, R. Lanzenberger, Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. *Neuroimage* **176**, 259-267 (2018).
73. T. K. Karikari, T. A. Pascoal, N. J. Ashton, S. Janelidze, A. L. Benedet, J. L. Rodriguez, M. Chamoun, M. Savard, M. S. Kang, J. Therriault, M. Scholl, G.

- Massarweh, J. P. Soucy, K. Hoglund, G. Brinkmalm, N. Mattsson, S. Palmqvist, S. Gauthier, E. Stomrud, H. Zetterberg, O. Hansson, P. Rosa-Neto, K. Blennow, Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. *Lancet Neurol* **19**, 422-433 (2020).
74. J. Lerch, C. Hammill, M. van Eede, D. Cassel. (2017).
75. Y. Rosseel, lavaan: An R Package for Structural Equation Modeling. *Journal of Statistical Software* **48**, 1–36 (2012).
76. R. O. Mueller, G. R. Hancock, in *Best Practices in Quantitative Methods*, J. Osborne, Ed. (SAGE, 2008), chap. 32, pp. 488-508.
77. K. Schermelleh-Engel, H. Moosbrugger, H. Müller, Evaluating the Fit of Structural Equation Models: Tests of Significance and Descriptive Goodness-of-Fit Measures. *Methods of Psychological Research* **8**, 23-74 (2003).

Acknowledgments: We acknowledge all study participants and the staff of the McGill University Research Center for Studies in Aging. We thank Dean Jolly, Alexey Kostikov, Monica Samoila-Lactatus, Karen Ross, Mehdi Boudjemeline, and Sandy Li for assisting in the radiochemistry production, as well as Richard Strauss, Edith Strauss, Guylaine Gagné, Carley Mayhew, Tasha Vinet-Celluci, Karen Wan, Sarah Sbeiti, Meong Jin Joung, Miloudza Omand, Rim Nazar, Hung-Hsin Hsiao, Reda Bouhachi, and Arturo Aliaga for helping with the acquisition of the data. We also acknowledge Simon Jones and Leonidas Chouliaras at the University of Cambridge for discussing the findings. The

views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Funding:

Alzheimer's Association (#NIRG-12-92090 and #NIRP-12-259245; PR-N)

Alzheimer's Association (#AACSF-20-648075; TAP)

Brain & Behavioral Research Foundation (#29486; DTL)

Brain Canada Foundation (CFI Project 34874; 33397; PR-N)

Canadian Consortium of Neurodegeneration and Aging (#MOP-11-51-31 - team 1; PR-N)

Canadian Institutes of Health Research (#MOP-11-51-31; RFN 152985, 159815, 162303; PR-N)

CNPq (200691/2021-0; JPF-S)

CNPq (166407/2020-8; DTL)

Fonds de Recherche du Québec – Santé (Chercheur Boursier, #2020-VICO-279314; PR-N)

Fonds de Recherche du Québec – Santé (FZL)

National Institutes of Health (#R01AG075336 and #R01AG073267; TAP)

Race Against Dementia Alzheimer's Research UK (#ARUK-RADF2021A-010; MM)

Weston Brain Institute (PR-N)

Author contributions:

Conceptualization: JPF-S, FZL, PR-N, and TAP

Methodology: JPF-S, FZL, and TAP

Formal analysis: JPF-S, FZL, CT, and DLT

Investigation: JPF-S, FZL, DTL, JT, CT, BB, PCLF, MM, Y-TW, GP, ALB, NJA, MC, SS, GB, MSK, JS, NR, VP, NMP, TKK, ERZ, PR-N, TAP

Resources: HZ, KB, PR-N

Writing - Original Draft: JPF-S

Writing - Review & Editing: JPF-S, FZL, DTL, JT, CT, BB, PCLF, MM, GP, ALB, NJA, JTO, JBR, AC, OLL, DLT, TKK, WEK, VLV, J-PS, SG, DOS, HZ, KB, ERZ, PR-N, and TAP

Supervision: TAP

Project administration: JPF-S, PR-N, TAP

Funding acquisition: JPF-S, PR-N, TAP

Competing interests: SG has served as a scientific advisor to Cerveau Therapeutics. HZ

has served at scientific advisory boards and/or as a consultant for Abbvie, Alector, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Pinteon Therapeutics, Red Abbey Labs, reMYND, Passage Bio, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. KB has served as a

consultant, at advisory boards, or at data monitoring committees for Abcam, Axon, BioArctic, Biogen, JOMDD/Shimadzu. Julius Clinical, Lilly, MagQu, Novartis, Prothena, Roche Diagnostics, and Siemens Healthineers, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program. ERZ serves in the scientific advisory board of Next Innovative Therapeutics. All other authors declare that they have no competing interests.

Data and materials availability: The data used in the present work is not publicly available as the information could compromise the participants' privacy. Therefore, the data from the TRIAD study will be made available from the senior authors upon reasonable request, and such arrangements are subject to standard data-sharing agreements.

Table 1. Demographics and key characteristics of participants by clinical diagnosis.

	CU	MCI	AD
No.	79	23	16
Age, years	72.3 (5.7)	73.0 (5.3)	70.1 (10.3)
Male, No. (%)	17 (21.5)	14 (60.9)	9 (56.3)
Education, years	15.2 (3.7)	15.5 (2.9)	13.6 (3.8)
<i>APOE</i> ε4 carrier, No. (%)	23 (29.1)	15 (65.2)	7 (43.8)
MMSE score	29.2 (1.0)	28.2 (1.6)	22.1 (5.9)
CDR-SB score	0.1 (0.2)	1.5 (0.8)	5.3 (2.5)
Global [¹⁸ F]AZD4694 SUVR	1.52 (0.43)	2.18 (0.58)	2.42 (0.54)
Braak I-II [¹⁸ F]MK6240 SUVR	0.94 (0.19)	1.38 (0.52)	1.60 (0.39)
Braak III-IV [¹⁸ F]MK6240 SUVR	0.96 (0.10)	1.28 (0.53)	2.19 (1.13)
Braak V-VI [¹⁸ F]MK6240 SUVR	0.98 (0.09)	1.16 (0.31)	2.05 (1.22)
Hippocampal volume, cm ³	3.45 (0.34)	3.18 (0.34)	2.95 (0.55)

Continuous variables are presented as mean (SD). Abbreviations: AD = Alzheimer's disease; *APOE*ε4 = Apolipoprotein E ε4; CDR-SB = clinical dementia rating scale sum of boxes; CU = cognitively unimpaired; MCI = mild cognitive impairment; MMSE = Mini-Mental State Examination; ROI = region of interest; SD = standard deviation; SUVR = standardized uptake value ratio.

Table 2. The association between *APOE*ε4 carriership and microglial activation is independent of Aβ and tau PET.

	β (95% CI)	T-value	P-value
Model: [¹¹C]PBR28 SUVR ~ <i>APOE</i>ε4 status + [¹⁸F]AZD4694 SUVR + [¹⁸F]MK6240 SUVR + age + sex + clinical diagnosis			
<i>APOE</i> ε4 carriership	0.055 (0.010 to 0.100)	2.404	0.018
[¹⁸ F]AZD4694 SUVR	-0.030 (-0.079 to 0.019)	-1.203	0.232
[¹⁸ F]MK6240 SUVR	0.109 (0.031 to 0.187)	2.779	0.006
Age	0.001 (-0.002 to 0.004)	0.631	0.530
Male	-0.015 (-0.061 to 0.031)	-0.656	0.513
Clinical diagnosis			
MCI	-0.064 (-0.129 to 0.001)	-1.954	0.053
AD	-0.071 (-0.151 to 0.009)	-1.758	0.082

Aβ pathology was measured with global [¹⁸F]AZD4694 SUVR, microglial activation with Braak I-II [¹¹C]PBR28 SUVR, and tau pathology with Braak I-II [¹⁸F]MK6240 SUVR. Abbreviations: AD = Alzheimer’s disease; *APOE*ε4 = Apolipoprotein E ε4; Aβ = amyloid-β; CI = confidence interval; MCI = mild cognitive impairment; SUVR = standardized uptake value ratio.

Figures




Fig. 1. *APOE*ε4 carriership is associated with microglial activation in early Braak regions. (A) T-map shows the result of voxel-wise linear regression testing the association of *APOE*ε4 carriage status (noncarrier or carrier) with [¹¹C]PBR28 SUVR accounting for

age, sex, and clinical diagnosis (CU, MCI, or AD). Results survived random field theory correction for multiple comparisons at $P < 0.05$. **(B)** Bars show the mean and standard deviation of [^{11}C]PBR28 SUVR in *APOE* ϵ 4 noncarriers and carriers. Imaging biomarker values were extracted from the peak *T*-value cluster of the voxel-wise analysis (*T*-value ≥ 4.7). *P*-value indicates the result of regression analysis accounting for age, sex, and clinical diagnosis. **(C)** Bars represent the spatial extent of the *APOE* ϵ 4-related microglia activation across Braak regions. Values were calculated by determining the percentage of voxels per Braak region having an association (*T*-value > 2) between *APOE* ϵ 4 carriership and [^{11}C]PBR28 in the voxel-wise analysis. **(D)** β estimates with 95% CI represent the strength of the regional association between *APOE* ϵ 4 status and [^{11}C]PBR28 SUVR across Braak regions from ROI-based linear regressions. Models were adjusted for age, sex, and clinical diagnosis. Estimates that survived Bonferroni correction at $P < 0.05$ are indicated with a double asterisk.




Fig. 2. The brain levels of *APOE* gene expression predict *APOE*ε4-related [¹¹C]PBR28 SUVR increase. (A) Brain map of the topographical distribution of *APOE* mRNA expression in 6 CU individuals obtained from the Allen Human Brain Atlas (left). Average intensity values of *APOE* mRNA expression in each Braak region (right). **(B)** Regression analysis testing whether Allen *APOE* gene expression patterns predict the percentage of the area showing *APOE*ε4-related [¹¹C]PBR28 SUVR increase across Braak regions in our population. **(C)** Regression analysis testing whether the Allen brain *APOE* gene expression patterns predict the magnitude/strength of the association between *APOE*ε4 and [¹¹C]PBR28 uptake across Braak regions in our population.




Fig. 3. *APOEε4* contributes to AD progression independently of Aβ by activating microglia. The values presented in the figure are structural equation model β estimates testing the associations between *APOEε4* status, microglial activation PET, Aβ PET, tau PET, hippocampal volume, and clinical function. Given that the β estimates presented in the figure are standardized, the effects can be directly compared. Solid lines represent significant associations, whereas dashed lines represent non-significant effects. All associations were adjusted for age and sex. Associations involving hippocampal volume and clinical function were also adjusted for years of education. Aβ pathology was measured with global [¹⁸F]AZD4694 SUVR, microglial activation with Braak I-II [¹¹C]PBR28 SUVR, and tau pathology with Braak I-II [¹⁸F]MK6240 SUVR. Clinical function was assessed with the CDR-SB score.